Rituximab-PECC induction followed by 90 Y-ibritumomab tiuxetan consolidation in relapsed or refractory DLBCL patients who are ineligible for or have failed ASCT: results from a phase II HOVON study

Dutch HOVON group, Pieternella J Lugtenburg, Josee M Zijlstra, Jeanette K Doorduijn, Lara H Böhmer, Mels Hoogendoorn, Henriette W Berenschot, Aart Beeker, Nicole C van der Burg-de Graauw, Harry C Schouten, Yavuz M Bilgin, Marie-Jose Kersten, Harry R Koene, Alexandra H E Herbers, Daphne de Jong, Nathalie Hijmering, King H Lam, Dana Chiţu, Rolf E Brouwer, Gustaaf W van Imhoff

Research output: Contribution to journalArticleAcademicpeer-review

7 Citations (Scopus)

Abstract

Patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) after, or ineligible for, autologous stem cell transplantation (ASCT) have a dismal prognosis. This phase II study evaluated treatment with R-PECC (rituximab, prednisolone, etoposide, chlorambucil, lomustine), every 28 days for 4 cycles in 62 patients, followed by radio-immunotherapy consolidation with 90 Y-ibritumomab tiuxetan in responsive patients. Primary endpoints were failure-free survival (FFS) and incidence of grade ≥3 adverse events from start of 90 Y-ibritumomab tiuxetan. The overall response rate after R-PECC was 50%. Twenty-nine of 31 responsive patients proceeded to 90 Y-ibritumomab tiuxetan. Five out of 15 partial remission patients converted to complete remission after 90 Y-ibritumomab tiuxetan. One-year FFS and overall survival (OS) from start of 90 Y-ibritumomab tiuxetan was 52% (95% confidence interval [CI], 33-68%) and 62% (95% CI, 42-77%), respectively. One-year FFS and OS from start of R-PECC was 28% (95% CI, 17-39%) and 49% (95% CI, 36-61%), respectively. Toxicities of R-PECC and 90 Y-ibritumomab tiuxetan were mainly haematological. In conclusion, for relapsed DLBCL patients the largely oral R-PECC regimen achieves promising response rates, combined with an acceptable safety profile. Consolidation with 90 Y-ibritumomab tiuxetan resulted in long-term response durations in approximately one third of the patients that received it.

Original languageEnglish
Pages (from-to)347-355
Number of pages9
JournalBritish Journal of Haematology
Volume187
Issue number3
DOIs
Publication statusPublished - Nov 2019

Bibliographical note

Funding:
This work was supported by the Dutch Cancer Society
[CKTO 2007-10]. Spectrum and Bayer Schering Pharma
AG supplied 90Y-ibritumomab tiuxetan.

© 2019 British Society for Haematology and John Wiley & Sons Ltd.

Research programs

  • EMC MM-02-41-03
  • EMC MM-03-24-01

Fingerprint

Dive into the research topics of 'Rituximab-PECC induction followed by 90 Y-ibritumomab tiuxetan consolidation in relapsed or refractory DLBCL patients who are ineligible for or have failed ASCT: results from a phase II HOVON study'. Together they form a unique fingerprint.

Cite this